Another fusion antibody, L19-IL-2, targeting the EDB domain of FN combined with the IL2, was effective in an animal model and achieved stable condition in a clinical trial including patients with melanoma and renal cell carcinoma (Carnemolla et al., 2002; Eigentler et al., 2011). This evidence concerns the gene IL2 and renal cell carcinoma.